Novel delivery system with a dual–trigger release of savory essential oil by mesoporous silica nanospheres and its possible targets in leukemia cancer cells: in vitro study

Table 5 Summary of the possible targeting specifications in HL60 cancer cells by nanoformulations and free SA natural agent

Targeting specification	Treatments			Therapeutic efficacy (As general effect)
Targeting specification	Nanoformulations	SA	STS	Therapeutic efficacy (As general effect)
Caspase–3	Up	Up	Up	Nanoformulations > SA > STS
Cytochrome c	Up	Up	Up	Nanoformulations > SA > STS
ROS	Up	Up	Up	Nanoformulations > SA > STS
Tubulin inhibition	Up	Up	Up*	Nanoformulations > COL > SA
BAX	Up	Up	Up	STS > nanoformulations > SA
Bcl–2	Down	Down	Down	Nanoformulations > SA > STS
P21	Up	Up	Up	Nanoformulations > SA > STS
PARP1	Down (little)	Up (little)	Up (little)	Nanoformulations < SA < STS
CDK1	Down	Down	Down	Nanoformulations < STS < SA
MAPK	Down	Down	Down	STS < SA < nanoformulations
HOTAIR	Down	Down	Down	SA < nanoformulations < STS
HULC	Down	Down	Down	SA < nanoformulations < STS
CCAT1	Down	Down	Down	Nanoformulations < SA < STS
H19	Down	Down	Down	SA < nanoformulations < STS
MMP–2	Down	Down	Down	nanoformulations < SA < STS
MMP–9	Down	Down	Down	Nanoformulations < SA < STS

^*The standard drug used was colchicine as a tubulin inhibitor. Up and down refer to the expression or level of tested markers. Up means that the treatment promotes the regulation of the tested marker, and down means that the treatments inhibit the regulation of the maker

ISSN: 1868-6966